Is there something other than imatinib mesilate in therapeutic options for GIST? - Wikidata - awgldk - TriplyDB

Is there something other than imatinib mesilate in therapeutic options for GIST?

Is there something other than imatinib mesilate in therapeutic options for GIST?

http://www.wikidata.org/entity/Q34207379

about

Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.BEX1 promotes imatinib-induced apoptosis by binding to and antagonizing BCL-2 Perforation as a rare presentation of gastric gastrointestinal stromal tumours: a case report and review of the literature Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors.

P2860

Q30593460-048B05D9-FA66-414B-92E7-61B7250BCF21 Q31153995-3A31580D-0100-4735-BBEF-73671912EDBC Q38177908-9460BCD4-83C4-4EF3-A485-46C03556FE1A Q39362495-16ED40B9-1128-429F-A88C-36AC74A54AE5

P2860

Is there something other than imatinib mesilate in therapeutic options for GIST?

http://www.wikidata.org/entity/Q34207379

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Is there something other than imatinib mesilate in therapeutic options for GIST?

@ast

Is there something other than imatinib mesilate in therapeutic options for GIST?

@en

Is there something other than imatinib mesilate in therapeutic options for GIST?

@nl

type

label

Is there something other than imatinib mesilate in therapeutic options for GIST?

@ast

Is there something other than imatinib mesilate in therapeutic options for GIST?

@en

Is there something other than imatinib mesilate in therapeutic options for GIST?

@nl

prefLabel

Is there something other than imatinib mesilate in therapeutic options for GIST?

@ast

Is there something other than imatinib mesilate in therapeutic options for GIST?

@en

Is there something other than imatinib mesilate in therapeutic options for GIST?

@nl

P1433

Q34207379-28BDA8F2-5C18-447C-8052-3BFEEC809305

P1476

Q34207379-E829920C-8C10-4D49-BE21-73E3168B47B2

P2093

Q34207379-653933C3-14CF-494B-9478-12ED44A413F9

Q34207379-90528BDA-668B-4E05-938E-251043E46519

P2860

Q34207379-05687678-01F6-413A-87B0-87CDDDEE081E

Q34207379-100D4544-4E29-4F57-B5C5-79C2CF14EC61

Q34207379-196F0E47-431E-4765-9D8E-D9332ECB2017

Q34207379-1E7003FA-5D5C-4274-AC57-8D70B21F5850

Q34207379-3A0ADAE0-C9AC-4013-A205-3AF6434023E3

Q34207379-3C4DBD71-54D0-4F2C-8055-F5FED7BCDA01

Q34207379-48288F1C-868E-4B9A-A7EA-E59D0A7092C6

Q34207379-4921D3BB-5FDC-47C7-800C-5A9FD8D89EEC

Q34207379-4AAC7018-FFF5-4BBF-9122-C76BD2F3B556

Q34207379-4B042D31-D8E1-482F-A4CA-4EE0F9290A76

P304

Q34207379-1989C23D-00D2-4D89-B18C-1F2CE48D8679

P31

Q34207379-933C1D8E-5058-4321-AAB0-86BE27566FED

P356

Q34207379-ED27632E-20E8-44E3-9FFF-146057F1ADAF

P407

Q34207379-03AECE10-F3D0-413C-8E7B-EA3C4BAB519F

P478

Q34207379-D9581D2B-8DD1-41D2-9D1B-DE188B9B025F

P577

Q34207379-2E4610CD-8018-4AA2-9B68-E0B2B7A92256

P698

Q34207379-7C357CBA-BD72-43D2-9674-33B94B5FA764

P356

14728222.2012.657627

P1433

Expert Opinion on Therapeutic Targets

P1476

Is there something other than imatinib mesilate in therapeutic options for GIST?

@en

P2093

Francesco Giuliani

http://www.w3.org/2001/XMLSchema#string

Giuseppe Colucci

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

P304

S35-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2012.657627

http://www.w3.org/2001/XMLSchema#string

P407

P478

16 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22443297

http://www.w3.org/2001/XMLSchema#string